Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Glaucoma: Overview01:25

Glaucoma: Overview

1.5K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.5K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Cases of Invasive Rhino-Orbital-Cerebral Mucormycosis in 2 Patients Who had Recently Recovered From Coronavirus Disease 2019.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2023
Same author

Size Matters: Ab Interno Canaloplasty Revision with Suture Trabeculotomy.

Journal of current glaucoma practice·2023
Same author

A Case of Leber Hereditary Optic Neuropathy Triggered by Pfizer-BioNTech Vaccine: Evidence of Pathogenesis of a Novel Mutation.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same author

An unusual presentation of convergence insufficiency in a patient with Parkinson's disease stimulated by deep brain stimulation.

American journal of ophthalmology case reports·2022
Same author

Alternating Unilateral and Bilateral Benign Episodic Pupillary Dilation.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same author

Delayed Onset of a Contralateral "White-Eyed Shunt" Posterior Draining Carotid-Cavernous Fistula Following Ipsilateral "Red-Eyed Shunt".

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K

Ethambutol optic neuropathy.

Paul D Chamberlain1, Ama Sadaka, Shauna Berry

  • 1aBaylor College of Medicine bDepartment of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital cDepartments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medicine dDepartment of Ophthalmology, UTMB, Galveston, University of Iowa Hospitals and Clinics, Texas A and M College of Medicine eUniversity of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Current Opinion in Ophthalmology
|August 1, 2017
PubMed
Summary
This summary is machine-generated.

Ethambutol-induced optic neuropathy (EON) affects about 1% of patients on recommended doses, posing a risk of vision loss. Early detection through regular screening and prompt management are crucial for preventing irreversible blindness.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K

Related Experiment Videos

Last Updated: Feb 25, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Neurology

Background:

  • Ethambutol is a key medication for tuberculosis treatment.
  • Ethambutol-induced optic neuropathy (EON) is a serious, potentially irreversible complication.
  • Preventable blindness associated with ethambutol necessitates heightened clinical awareness.

Purpose of the Study:

  • To summarize the epidemiology, clinical findings, management, and outcomes of EON.
  • To emphasize the importance of patient and physician education for EON prevention.
  • To highlight the need for timely and appropriate screening protocols for EON.

Main Methods:

  • Review of epidemiological studies on EON prevalence.
  • Evaluation of optical coherence tomography (OCT) for EON screening.
  • Analysis of clinical findings and management strategies for EON.

Main Results:

  • EON prevalence ranges from 0.7% to 1.29% at World Health Organization (WHO)-recommended ethambutol doses.
  • Optical coherence tomography (OCT) shows decreased retinal nerve fiber layer (RNFL) thickness in symptomatic EON.
  • OCT's ability to detect EON in asymptomatic patients requires further research.

Conclusions:

  • EON is a significant complication of ethambutol therapy, occurring in approximately 1% of patients at standard doses.
  • Regular ophthalmological screening, including visual field testing, is essential for all patients on ethambutol.
  • Prompt discontinuation or dose reduction of ethambutol is critical upon detection of EON signs or symptoms.